MAM
Geometry Encompass collaborates with Ankur Tewari and Clinton Cerejo to co-create a lockdown anthem ‘We Got This’ with the team
Geometry Encompass, India’s largest Creative Commerce agency and a part of WPP, recently collaborated with leading Singer, Song-writer Ankur Tewari and music director and composer Clinton Cerejo to co-create a song called ‘We Got This’. The song is an anthem that captures the spirit of team Geometry Encompass during these trying times of the global lockdown.
The song was conceptualized during an inspiring 2 hour long session between the team at Geometry Encompass with Clinton Cerejo and Ankur Tewari. Roshan Abbas, who originally thought of the idea as fun way to engage with the team invited everyone to share their thoughts and experiences during the lockdown. The thoughts that were shared were developed as the lyrics and hook words for the song. While Roshan and Ankur guided the creation of the lyrics, Clinton worked his magic with the music.
The song ‘We Got This’, is all about being a resilient and reiterates the power of unity and hope.
Commenting on the same, Roshan Abbas, Founder and Managing director, Geometry Encompass said, “We are faced with an unprecedented situation and therefore it is imperative to work together as a team and combat the crisis. The whole idea behind this composition was to capture the spirit of hope and resilience during these difficult times and boost the morale of our employees. I can’t thank Ankur and Clinton enough for being part of this creative collaboration”.
Ranjit Raina, CEO, Geometry Encompass said, “As an agency we have always strived to stay idea first and people focused. The collaboration was a great way to stay creative and connected. It’s a great way to celebrate the team and the work that we have managed to pull off even during the lockdown. Like the song says, “We Got This!”
Commenting on their collaboration, Ankur Tewari, Singer and Song-writer said, “I have always believed that words in a song bring in the most human element sort. It was quite amazing working with the whole geometry encompass team to work on the words for ‘we got this’. Despite of being probably the first time that most of these people working on a song, they showed amazing initiative, imagination and Enthusiasm to come up with extraordinary words for Clinton’s beautiful composition.”
Clinton Cerejo, Music Composer, said, “In these trying times, it’s all about innovation and breaking boundaries in your head. If we truly find ways to challenge ourselves, we can overcome anything. We got this.”
Here is the link to the film: https://www.youtube.com/watch?v=ZmG342JwACo&t=1s
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
